Filter Results:
(185)
Show Results For
- All HBS Web (185)
- Faculty Publications (19)
Show Results For
- All HBS Web (185)
- Faculty Publications (19)
Page 1 of 185
Results →
- 01 May 2019
- News
Getting Personal With Precision Medicine
- 24 Apr 2014
- News
Medicine made personal
Australia-born Arjun Goyal (MBA 2014) credits HBS with helping him focus his career on life sciences, specifically “personalized medicine”—a tailored approach to treatment based on analysis of patient populations. With his classmate Louis Levy (MBA 2014), whom he met... View Details
- 23 Jan 2019
- News
The Promise of Personalized Medicine
the foundation now for a bit over a year, and we didn’t get oriented around this personalized medicine mission until a few months in. So, more or less, we’ve been at this View Details
- October 2007
- Article
Realizing the Promise of Personalized Medicine
By: Mara G. Aspinall and Richard G. Hamermesh
Keywords: Health
Aspinall, Mara G., and Richard G. Hamermesh. "Realizing the Promise of Personalized Medicine." Harvard Business Review 85, no. 10 (October 2007).
- 18 Nov 2015
- News
Kraft foundation gives $20 million to advance personalized medicine
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement... View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details
Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- Article
The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making
By: Joshua Lev Krieger, Fiona Murray, J. Scott Roberts and Robert C. Green
Krieger, Joshua Lev, Fiona Murray, J. Scott Roberts, and Robert C. Green. "The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making." Nature Biotechnology 34, no. 9 (September 2016): 912–918.
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- 01 Dec 2013
- News
Your Own Medicine
not going anywhere. What are we doing wrong?" Frustrated, they hit up their network, looking for some way to put these kinds of potential cures into motion. "If you are trying to do something innovative in biotech, the person you need to... View Details
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- November 2012 (Revised January 2013)
- Case
Companion Diagnostics: Uncertainties for Approval and Reimbursement
By: Richard G. Hamermesh, Norman C. Selby and Phillip Andrews
The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory... View Details
Keywords: Models Of Reimbursement; Personalized Medicine; Regulation; Healthcare Reform; Health Care and Treatment; Health Industry; United States
Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, November 2012. (Revised January 2013.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- Article
One Obstacle to Curing Cancer: Patient Data Isn't Shared
By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
- 04 Oct 2018
- News
Precision medicine needs a business mindset in order to flourish
- 16 Dec 2016
- News
Search for a Youth Medicine Never Grows Old
- 13 Mar 2023
- Research & Ideas
The Power of Personal Connections: How Shared Experiences Boost Performance
Professor of Medicine at Harvard Medical School. So, what does the connection between patient outcomes and physician relationships mean for business? It shows how personal connections and trust can improve... View Details
- 2018
- Working Paper
Two Hundred Years of Health and Medical Care: The Importance of Medical Care for Life Expectancy Gains
By: Maryaline Catillon, David Cutler and Thomas Getzen
Using two hundred years of national and Massachusetts data on medical care and health, we examine how central medical care is to life expectancy gains. While common theories about medical care cost growth stress growing demand, our analysis highlights the importance of... View Details
Keywords: Mortality; Life Expectancy; Medical Care; Productivity; Public Health; Healthcare Spending; Spending Per Year Of Life Gained; Personal Medicine; Technophysio Evolution; Health; Economics; Health Care and Treatment; Spending; Data and Data Sets; Health Industry
Catillon, Maryaline, David Cutler, and Thomas Getzen. "Two Hundred Years of Health and Medical Care: The Importance of Medical Care for Life Expectancy Gains." NBER Working Paper Series, No. 25330, December 2018.
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)